Select Transactions

Acquisition of
generics business of
$1.05 billion
June 2017
Mallinckrodt Pharmaceuticals
Sale of
Intrathecal business to
$203 million
March 2017
Assembly Biosciences
Microbiome partnership with
$2.6 billion
($50 million upfront)
January 2017
HealthCare Royalty Partners
acquisition financing
for undisclosed
spec pharma
$100 million
February 2016
Torreya is a leading strategic M&A advisor to global life sciences companies.   MORE
Torreya is one of the most active financial advisors on pharmaceutical-product asset sales.   MORE
Torreya’s Capital Markets team arranges debt financings, royalty monetizations, IPOs, and private equity recapitalizations.   MORE
Torreya is a leading advisor on pre-commercial and commercial-stage licensing deals.   MORE

The Future of the Global Pharmaceutical Industry

Torreya finds the global pharmaceutical industry is larger, innovating more rapidly, and likely to experience higher growth than previously thought.

Click here for Report Executive Summary   |    Click here for full Future of Global Pharmaceutical Industry Report

1 Based on Torreya econometric model relating OECD estimates of future GDP growth to growth estimates for the pharmaceutical sector.